Seelos Therapeutics (SEEL) Peer Comparison
$0.25
$-0.92
(-78.63%)
As on 17-Dec-2024 09:30EDT
Market cap
$0 Mln
Revenue (TTM)
$2 Mln
P/E Ratio
0
P/B Ratio
15.1
Div. Yield
0 %
Edit
| Seelos Therapeutics (SEEL) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
0 | 14,975 | 12,310 | 11,972 | 10,425 |
Revenue ($ Mln) |
2 | 692 | 831 | 5,020 | 777 |
Net Profit ($ Mln) |
4.09 | -696.24 | 54.90 | -199.00 | -191.64 |
Net Margin (%) |
203.13 | -100.64 | 6.61 | -3.96 | -24.68 |
RoE (%) |
-- | -- | 8.11 | -3.03 | -223.36 |
Price to Earnings |
0.00 | -- | 264.84 | -- | -- |
Price-To-Book |
15.10 | 123.68 | 17.91 | 1.79 | 129.60 |
Income Statement ($ Mln)
| Seelos Therapeutics (SEEL) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
2.01 | 9.30 | 482.38 | 4,417.00 | 270.60 |
|
Cost of Revenue
|
0.06 | 2.45 | 6.48 | 2,479.00 | 26.07 |
|
Gross Profit
|
2.15 | 6.86 | 475.89 | 1,938.00 | 244.54 |
|
Operating Expenses
|
31.78 | 614.23 | 368.61 | 1,612.00 | 476.36 |
|
Operating Profit (EBIT)
|
-29.81 | -607.37 | 107.28 | 326.00 | -231.83 |
|
Other Income
|
0.00 | 107.99 | -- | -32.00 | -- |
|
Profit before Tax
|
4.09 | -653.25 | 124.56 | -1,195.00 | -238.28 |
|
Provision for Tax
|
-0.04 | 71.51 | 18.42 | 36.00 | 0.96 |
|
Profit after Tax (Net Income)
|
4.09 | -643.20 | 106.14 | -1,231.00 | -239.24 |
|
Minority Interest
|
0.00 | 11.28 | -- | -- | -- |
|
Consolidated Profit
|
0.00 | -481.18 | 101.29 | -78.00 | -187.13 |
Liabilities ($ Mln)
| Seelos Therapeutics (SEEL) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-28.13 | -1,354.26 | 506.71 | 6,223.00 | 190.98 |
|
Minority Interest
|
0.00 | 11.28 | -- | -- | -- |
|
Non-Current Liabilities
|
0.00 | 1,745.07 | 10.31 | 6,898.00 | 258.41 |
|
Current Liabilities
|
30.51 | 143.84 | 104.51 | 1,241.00 | 138.85 |
|
Total Liabilities
|
5.42 | 546.38 | 621.52 | 14,362.00 | 588.24 |
Assets ($ Mln)
| Seelos Therapeutics (SEEL) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.05 | 68.79 | 162.88 | 10,955.00 | 83.97 |
|
Current Assets
|
2.33 | 477.59 | 458.64 | 3,407.00 | 504.26 |
|
Total Assets
|
5.42 | 546.38 | 621.52 | 14,362.00 | 588.24 |
|
Total Debt*
|
10.16 | 1,739.84 | 0.15 | 5,774.00 | 186.37 |
|
Net Current Assets
|
-28.18 | 333.75 | 354.13 | 2,166.00 | 365.41 |
Cashflow ($ Mln)
| Seelos Therapeutics (SEEL) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-23.91 | -527.72 | 127.04 | 271.00 | -145.08 |
|
Cash Flow from Investing Activities
|
-- | 54.03 | 90.91 | -169.00 | -0.58 |
|
Cash from Financing Activities
|
11.38 | 451.54 | -148.72 | -83.00 | 331.01 |
|
Net Cash Inflow / Outflow
|
-- | 20.52 | -- | -276.00 | -- |
Ratios
Profitability Ratios
| Seelos Therapeutics (SEEL) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
775.40 | -150.54 | 21.02 | -9.80 | -82.27 |
|
ROE (%)
|
171.72 | 49.31 | 21.05 | -18.22 | -159.21 |
|
ROA (%)
|
8.11 | -110.00 | 17.62 | -8.25 | -52.02 |
|
EBIT Margin (%)
|
-1,480.73 | -- | -- | -- | -- |
|
Net Margin (%)
|
203.13 | -6,913.92 | 22.00 | -27.87 | -88.41 |
|
Cash Profit Margin (%)
|
0.00 | -- | -- | -- | -- |
Growth Ratios
| Seelos Therapeutics (SEEL) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
76.05 | -0.88 | 0.20 | 0.00 | 4.41 |
|
EBIT Growth (%)
|
46.24 | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
104.67 | -33.67 | 4.66 | -1,478.21 | -27.84 |
|
EPS Growth (%)
|
108.98 | -0.14 | 0.10 | -14.64 | -0.17 |
|
Book Value Growth (%)
|
-4.24 | -- | -- | -- | -- |
Valuation Ratios
| Seelos Therapeutics (SEEL) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-0.36 | -10.95 | 33.93 | -5.96 | -15.75 |
|
Price / Book Value
|
-0.41 | -5.20 | 7.11 | 1.18 | 19.72 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-0.61 | -14.76 | 25.74 | -56.99 | -15.85 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Seelos Therapeutics (SEEL) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | -1.28 | 0.00 | 0.93 | 0.98 |
|
Short term debt to equity ratio
|
-0.36 | 0.00 | 0.00 | 0.01 | 0.01 |
|
Current Ratio
|
0.08 | 3.32 | 4.39 | 2.75 | 3.63 |
|
Quick Ratio
|
0.08 | 3.20 | 4.31 | 1.35 | 3.52 |
|
Interest Coverage
|
39.23 | -7.04 | 31.67 | -3.31 | -35.93 |
Operating Efficiency Ratios
| Seelos Therapeutics (SEEL) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
9.33 | 18.82 | 11.78 | 22.87 | 35.04 |
|
Asset Turnover
|
0.04 | 0.02 | 0.80 | 0.30 | 0.59 |
|
Receivable days
|
63.25 | 369.65 | 39.25 | 83.19 | 89.44 |
|
Inventory Days
|
0.01 | 4,075.31 | 389.71 | 241.12 | 136.31 |
|
Payable days
|
64,171.86 | 1,658.48 | 827.66 | 48.62 | 555.51 |
|
Cash Conversion Cycle
|
-64,108.60 | 2,786.48 | -398.70 | 275.68 | -329.76 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
